Norway · Delayed Price · Currency is NOK Medistim ASA Statistics
Total Valuation
Medistim ASA has a market cap or net worth of NOK 5.73 billion. The enterprise value is 5.58 billion.
| Market Cap | 5.73B |
| Enterprise Value | 5.58B |
Important Dates
The last earnings date was Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | Oct 27, 2026 |
Share Statistics
Medistim ASA has 18.29 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 18.29M |
| Shares Outstanding | 18.29M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 19.90% |
| Owned by Institutions (%) | 77.66% |
| Float | 11.35M |
Valuation Ratios
The trailing PE ratio is 32.10 and the forward PE ratio is 26.87.
| PE Ratio | 32.10 |
| Forward PE | 26.87 |
| PS Ratio | 7.19 |
| PB Ratio | 12.58 |
| P/TBV Ratio | 16.54 |
| P/FCF Ratio | 28.33 |
| P/OCF Ratio | 27.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.13, with an EV/FCF ratio of 27.59.
| EV / Earnings | 31.26 |
| EV / Sales | 7.01 |
| EV / EBITDA | 22.13 |
| EV / EBIT | 24.48 |
| EV / FCF | 27.59 |
Financial Position
The company has a current ratio of 3.16, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.16 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.13 |
| Interest Coverage | 418.81 |
Financial Efficiency
Return on equity (ROE) is 40.84% and return on invested capital (ROIC) is 54.24%.
| Return on Equity (ROE) | 40.84% |
| Return on Assets (ROA) | 23.48% |
| Return on Invested Capital (ROIC) | 54.24% |
| Return on Capital Employed (ROCE) | 45.82% |
| Weighted Average Cost of Capital (WACC) | 9.02% |
| Revenue Per Employee | 5.01M |
| Profits Per Employee | 1.12M |
| Employee Count | 159 |
| Asset Turnover | 1.31 |
| Inventory Turnover | 0.92 |
Taxes
In the past 12 months, Medistim ASA has paid 51.70 million in taxes.
| Income Tax | 51.70M |
| Effective Tax Rate | 22.47% |
Stock Price Statistics
The stock price has increased by +26.21% in the last 52 weeks. The beta is 0.87, so Medistim ASA's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +26.21% |
| 50-Day Moving Average | 275.64 |
| 200-Day Moving Average | 238.34 |
| Relative Strength Index (RSI) | 65.20 |
| Average Volume (20 Days) | 21,648 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medistim ASA had revenue of NOK 795.98 million and earned 178.39 million in profits. Earnings per share was 9.75.
| Revenue | 795.98M |
| Gross Profit | 650.18M |
| Operating Income | 227.83M |
| Pretax Income | 230.09M |
| Net Income | 178.39M |
| EBITDA | 243.17M |
| EBIT | 227.83M |
| Earnings Per Share (EPS) | 9.75 |
Balance Sheet
The company has 175.63 million in cash and 26.24 million in debt, with a net cash position of 149.39 million or 8.17 per share.
| Cash & Cash Equivalents | 175.63M |
| Total Debt | 26.24M |
| Net Cash | 149.39M |
| Net Cash Per Share | 8.17 |
| Equity (Book Value) | 455.11M |
| Book Value Per Share | 24.88 |
| Working Capital | 304.47M |
Cash Flow
In the last 12 months, operating cash flow was 207.62 million and capital expenditures -5.49 million, giving a free cash flow of 202.13 million.
| Operating Cash Flow | 207.62M |
| Capital Expenditures | -5.49M |
| Depreciation & Amortization | 15.33M |
| Net Borrowing | -11.92M |
| Free Cash Flow | 202.13M |
| FCF Per Share | 11.05 |
Margins
Gross margin is 81.68%, with operating and profit margins of 28.62% and 22.41%.
| Gross Margin | 81.68% |
| Operating Margin | 28.62% |
| Pretax Margin | 28.91% |
| Profit Margin | 22.41% |
| EBITDA Margin | 30.55% |
| EBIT Margin | 28.62% |
| FCF Margin | 25.39% |
Dividends & Yields
This stock pays an annual dividend of 8.00, which amounts to a dividend yield of 2.56%.
| Dividend Per Share | 8.00 |
| Dividend Yield | 2.56% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 81.80% |
| FCF Payout Ratio | 95.03% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 2.54% |
| Earnings Yield | 3.12% |
| FCF Yield | 3.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Medistim ASA is 365.00, which is 16.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 365.00 |
| Price Target Difference | 16.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 14.47% |
| EPS Growth Forecast (3Y) | 17.42% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |